Newly approved oral medication slows rheumatoid arthritis joint damage

Newly approved oral medication slows rheumatoid arthritis joint damage
A Phase 3 clinical trial demonstrates that tofacitinib improves disease activity and inhibits progression of joint damage in rheumatoid arthritis (RA) patients who did not respond to methotrexate (MTX). Results of the 12-month interim analysis of the …

Full News here – Read more on EurekAlert (press release)

Leave a Reply